This product is a CRISPR/Cas9-edited polyclonal knockout cell population of the HINT3 gene in the human NCI-H1975 cell line. The polyclonal nature ensures a diverse representation of gene-disrupted cells, providing a robust loss-of-function model for studying HINT3 biology without the clonal biases associated with single-cell-derived lines. The knockout was achieved through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous polyclonal population with targeted loss of HINT3 function. This format is particularly suited for experiments where population-level effects are of interest, such as signaling studies and drug response assays.
NCI-H1975 is a human lung adenocarcinoma epithelial cell line harboring the EGFR L858R mutation, a primary oncogenic driver in non-small cell lung cancer. This cell line is widely employed as a model for studying EGFR-mutant lung cancer, including mechanisms of drug resistance and tumor progression. Its adherent epithelial morphology and well-characterized signaling networks make it an ideal platform for investigating mitochondrial apoptosis pathways and cellular responses to therapeutic stress.
HINT3 encodes a mitochondrial histidine triad nucleotide-binding protein with adenosine monophosphoramidase activity, critical for maintaining mitochondrial nucleotide homeostasis and regulating apoptotic signaling. HINT3 functions within a network involving upstream regulators such as p53 and AMPK, which respond to mitochondrial stress signals. It interacts with key mitochondrial proteins including HINT2, VDAC1, ANT, and mitochondrial ribosome components. Downstream, HINT3 modulates the balance of pro- and anti-apoptotic BCL-2 family proteins, influencing cytochrome c release and subsequent activation of caspase-9, caspase-3, and APAF1. This positions HINT3 at a critical node between nucleotide metabolism and intrinsic apoptosis.
Disruption of HINT3 in NCI-H1975 cells disrupts mitochondrial nucleotide homeostasis, shifting the balance toward pro-apoptotic signaling. This sensitizes cells to apoptosis by promoting BAX/BAK activation and enhancing cytochrome c release, leading to increased caspase activation. In the context of EGFR-mutant lung adenocarcinoma, HINT3 knockout may reveal vulnerabilities linked to mitochondrial dysfunction and altered apoptotic thresholds, providing insights into potential therapeutic strategies that target mitochondrial pathways in drug-resistant cancers.
This polyclonal HINT3 knockout cell model is suitable for a wide range of experimental applications, including functional studies of HINT3 in lung adenocarcinoma, investigation of mitochondrial-mediated apoptosis, and drug sensitivity screening in EGFR-mutant NSCLC. Researchers can employ representative assays such as western blotting for apoptosis markers (e.g., cleaved caspase-3, cytochrome c), ATP level measurement, mitochondrial membrane potential assessment using JC-1, caspase-3 activity assays, cell viability assays with EGFR inhibitors, RT-qPCR for BCL-2 family gene expression, and clonogenic survival assays. This model offers a valuable tool for dissecting the role of HINT3 in nucleotide metabolism and apoptosis in cancer. For further details, please contact Ascent Research.
